Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/15/2007WO2007002390A3 Compositions and methods for modulation of smn2 splicing
11/15/2007WO2007000505A3 Derivatives of 4,5-diarylpyrrole, preparation method thereof and use of same in therapeutics
11/15/2007WO2007000043A3 Pyrazolo[3,4-b]pyridin-2-yl]-benzoic acid derivatives as hiv integrase inhibitors
11/15/2007WO2006135636A3 Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
11/15/2007WO2006128085A3 Cadherin-11-mediated modulation of hair growth
11/15/2007WO2006124354A3 Tyrosine kinase inhibitors
11/15/2007WO2006122319A3 Histone deacetylase inhibitors
11/15/2007WO2006121390A8 Benzoic acid derivatives that are modulators or agonists of glyr
11/15/2007WO2006119498A3 Pharmaceutical compositions with synchronized solubilizer release
11/15/2007WO2006118630A3 Phosphoinositide modulation for the treatment of alzheimer's disease
11/15/2007WO2006110813A3 Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
11/15/2007WO2006094737A8 Gastroresistant pharmaceutical formulations containing rifaximin
11/15/2007WO2006086456A3 Combination of organic compounds
11/15/2007WO2006086250A3 A catheter lock solution comprising citrate and a paraben
11/15/2007WO2006074149A3 Treatment of drug-resistant proliferative disorders
11/15/2007WO2006069668A8 Method for producing a raw oil from mixtures of micro-organisms and plants, oil produced according to said method and specific uses of the thus produced oil and, optionally, additional refined oil
11/15/2007WO2006052717A3 Glucuronide metabolites and epimers thereof of tigecycline
11/15/2007WO2006044090A3 Topical treatment with ngf and dha in damaged corneas
11/15/2007WO2006039704A3 Pharmaceutical composition and method for treating a joint capsule arthropathy
11/15/2007WO2006017816A3 Product and process for inhibition of biofilm development
11/15/2007WO2005094373A3 Cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase and methods to reduce pulmonary infiltration by neutrophils
11/15/2007WO2005089247A3 Antisense composition and method for treating cancer
11/15/2007WO2005069906A3 Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
11/15/2007WO2005059509A3 Biosensors for detecting macromolecules and other analytes
11/15/2007WO2005046572A3 Targeted delivery of controlled release polymer systems
11/15/2007WO2004103263A3 Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
11/15/2007WO2004073631A3 Combination therapy for the treatment of neoplasms
11/15/2007WO2004032856A3 Compounds
11/15/2007WO2002089799A3 Use of dihydropyrazoles to increase erythropoietin and vasculari zation
11/15/2007WO2002068586A3 Hiv/fiv protease inhibitors
11/15/2007WO2002019842A3 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
11/15/2007US20070265625 Spine distraction implant and method
11/15/2007US20070265624 Spine distraction implant and method
11/15/2007US20070265451 Process for the preparation of oxazolidinones and method of use thereof
11/15/2007US20070265450 Novel processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
11/15/2007US20070265449 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
11/15/2007US20070265446 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
11/15/2007US20070265440 Synthesis of 2-alkynyladenosine derivatives eg Trans-(1-[4-hydroxymethyl)cyclohexyl]methyl)-4-methylbenzenesulfonate
11/15/2007US20070265436 Nucleotide sequences coding tumor-associated antigenic target polypeptide specific immunoglobulins for use in detection and prevention of cell proliferative disorders
11/15/2007US20070265353 Eye Drops for the Treatment of Dry Eye
11/15/2007US20070265352 Synergistic mixtures of at least one 1,2 alkanediol such as 1,2-hexanediol and 1,2-octanediol with a further compound having antimicrobial properties
11/15/2007US20070265351 Novel xanthophyll composition containing trans, meso-zeaxanthin, trans, R, R-zeaxanthin and trans, R, R-lutein useful for nutrition and health care and a process for its preparation
11/15/2007US20070265350 Method of identifying compounds useful to treat neuronal degenerative diseases
11/15/2007US20070265349 Medicinal association of a biguanine and a carrier, for example metformin and arginine
11/15/2007US20070265348 Therapeutic guanidines
11/15/2007US20070265347 Encapsulated oil-in-water type emulsion composition
11/15/2007US20070265346 Combination therapy for the treatment and improvement of scars
11/15/2007US20070265345 Novel Biphenyl Compounds And Their Use
11/15/2007US20070265344 Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals
11/15/2007US20070265343 Method for alleviating signs and symptoms of spasticity
11/15/2007US20070265342 2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid; glutamate receptor agonist; antidepressant, anxiolytic agent; psychological, and psychiatric disorders
11/15/2007US20070265341 Compositions and methods for treating eye disorders and conditions
11/15/2007US20070265340 Treatment of fatty liver
11/15/2007US20070265339 for supporting metabolism in muscle tissue, and for supporting muscle structure, food supplements or veterinary animal feed additives
11/15/2007US20070265338 also contains taurine, sodium hyaluronate, vitamin E, manganese, zinc, sodium, and potassium
11/15/2007US20070265337 Method and composition for delivering zinc to the nasal membrane
11/15/2007US20070265336 Application of L-N-Butylphthalide in Preventing and Treating Dementia
11/15/2007US20070265335 Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsufonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same
11/15/2007US20070265334 Method for treating amyloidosis
11/15/2007US20070265333 For treatment of melanoma, colon cancer, and/or breast cancer
11/15/2007US20070265332 Antidiabetic bicyclic compounds
11/15/2007US20070265331 Such as (2S)-2-(3(S)-Acetylamino-3-((S)-sec-butyl)-2-oxo-pyrrolidin-1-yl)-N-[(1S,2R)-1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-4-phenyl-butyramide; inhibit processing of amyloid precursor proteins
11/15/2007US20070265330 Substituted gamma lactams as therapeutic agents
11/15/2007US20070265329 Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
11/15/2007US20070265328 2-(6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamides such as 4-(S)-hydroxy-5-(S)-[2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro(S)-[4.4]non-7-yl)-propionylamino]-2-(R)-methyl-6-phenyl-hexanoic acid butylamide; inhibitors of aspartic proteases such as beta-secretase
11/15/2007US20070265327 For therapy of neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal
11/15/2007US20070265326 Novel compounds
11/15/2007US20070265325 Nitro Indazole Derivatives
11/15/2007US20070265324 Such as veliparib and temozolomide; poly/adp-ribose/polymerase (PARP)
11/15/2007US20070265323 Compounds for the treatment of metabolic disorders
11/15/2007US20070265322 Compounds for the treatment of metabolic disorders
11/15/2007US20070265321 1,1-dioxo-isothiazolidine; glaucoma or ocular hypertension; prostaglandin receptor inhibitors
11/15/2007US20070265320 (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity
11/15/2007US20070265319 Neuroprotectants; reduce side effect of neurotoxic agent; treatment of neuropathies resulting from chemotherapeutic agents used in the treatment of HIV and proliferative disease such as cancer and treatment of inflammatory diseases, neurodegenerative diseases
11/15/2007US20070265318 Estrogen Receptor Modulators
11/15/2007US20070265317 Preparation of 3-[3-(Crotonylsulfanylmethylcarbonyloxy)-4-methoxyphenyl]-1-(3,4,5-trimethoxyphenyl)propenone (CMAC-1); breast, colon and colorectal, leukemia, pancreatic, central nervous system, non-small-cell lung, ovarian, prostate, melanoma, renal, fibrosarcoma, and urinary bladder cancer cells
11/15/2007US20070265316 2-(2-Chloro-benzoylamino)-4,5,6,7-tetrahydro-benzo thiophene-3-carboxylic acid amide; increasing activity of mutant-cystic fibrosis transmembrane conductance regulator protein in a cell; increasing halide ion permeability of a cell producing a Delta F508-CFTR protein
11/15/2007US20070265315 An urea compounds containing a pyridine, quinoline, or isoquinoline functionality; p38 mediated diseases such as inflammation and VEGF mediated diseases such as angogenesis disorders
11/15/2007US20070265313 Compositions use for increasing insulin sensitivity; formulations for minimizing the impurity associated with rosiglitazone maleate; safety and efficacy of product
11/15/2007US20070265312 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
11/15/2007US20070265311 Therapeutic Salt Compositions and Methods
11/15/2007US20070265310 Biphenyl compounds useful as muscarinic receptor antagonists
11/15/2007US20070265309 6-{5-[2R-(4-fluoro-phenyl)-4-methyl-piperazin-1-ylmethyl]-furan-3-yl}-3H-benzooxazol-2-one; Pyridine-2-carboxylic acid [4-fluoro-3-(1H-indol-5-yl)-benzyl]-(3-pyrrolidin-1-yl-propyl)-amide; for treating sleep disorders including insomnia and obstructive sleep apnea
11/15/2007US20070265308 5-[5-(2-chloro-4-fluorophenyl)-2-piperidin-4-yl-1,3-thiazol-4-yl]-1-(2,6-dichlorophenyl)pyridin-2(1H)-one; p38 MAP kinase inhibitory activity; inflammatory, respiratory , circulatory and central nervous diseases; rheumatoid arthritis
11/15/2007US20070265307 Administration of 4-aminopiperidine compounds for inducing and/or stimulating the growth of keratin fibers and/or preventing loss thereof
11/15/2007US20070265306 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
11/15/2007US20070265305 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; biphenyl carbamate derivative
11/15/2007US20070265304 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors
11/15/2007US20070265303 5-[(1R)-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one; chronic obstructive pulmonary disease (COPD), allergies
11/15/2007US20070265302 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
11/15/2007US20070265301 Dpp-IV Inhibitors
11/15/2007US20070265300 Pyridine Derivatives of Alkyl Oxindoles as 5-Ht7 Receptor Active Agents
11/15/2007US20070265299 Compounds for the treatment of inflammatory disorders
11/15/2007US20070265298 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity
11/15/2007US20070265297 Thiazolopyridine Derivatives, Pharmaceut Ical Conditions Containing Them And Methods Of Treating Glucokinase Mediated Conditions
11/15/2007US20070265296 Nuclear receptor binding agents
11/15/2007US20070265295 1-Heterocyclyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones
11/15/2007US20070265294 Formulations and methods for vascular permeability-related diseases or conditions
11/15/2007US20070265293 Opioid antagonists; lyophilization
11/15/2007US20070265292 N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-ylmethyl-benzamide methanesulfonate; anticarcinogenic and antproliferative agent; angiogenesis inhibitor
1 ... 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 ... 7860